Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: A cross-sectional study

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Dinh, Wilfried ^a,b,c   Lankisch, Mark ^a,b   Nickl, Werner ^a   Scheyer, Daniel ^a   Scheffold, Thomas ^a,d   Kramer, Frank ^e   Krahn, Thomas ^e   Klein, Rolf M ^f   Barroso, Michael C ^c   Füth, Reiner ^a,b  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b Helios Clinics Wuppertal   (Germany)

^c Institute for Sports Medicine ^*  (Germany)

^d Stiftung Institut für Herzinfarktforschung Ludwigshafen IHF   (Germany)

^e Global Biomarker Research   (Germany)

^f Augusta Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALLOPURINOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NITRATE; SULFONYLUREA DERIVATIVE; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; INSULIN;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CROSS-SECTIONAL STUDY; DIASTOLE; DIASTOLIC DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRACTICE GUIDELINE; BLOOD; CHI SQUARE DISTRIBUTION; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; GERMANY; GLUCOSE TOLERANCE TEST; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; GERMANY; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 77957898695     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-63     Document Type: Article

References (54)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989. 10.1016/j.ejheart.2008.08.005, 18826876.
2. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355:260-269. 10.1056/NEJMoa051530, 16855266.
3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355:251-259. 10.1056/NEJMoa052256, 16855265.
4. Mogelvang R, Sogaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, Goetze JP, Jensen JS. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. Circulation 2009, 119:2679-2685. 10.1161/CIRCULATIONAHA.108.793471, 19433761.
5. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787. 10.1038/414782a, 11742409.
6. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Ryden L. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005, 28:612-616. 10.2337/diacare.28.3.612, 15735197.
7. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30:595-602. 10.1016/0002-9149(72)90595-4, 4263660.
8. Raev DC. Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type I diabetic patients. Diabetes Care 1994, 17:633-639. 10.2337/diacare.17.7.633, 7924771.
9. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama 2003, 289:194-202. 10.1001/jama.289.2.194, 12517230.
10. Zabalgoitia M, Ismaeil MF, Anderson L, Maklady FA. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol 2001, 87:320-323. 10.1016/S0002-9149(00)01366-7, 11165968.
11. Stahrenberg R, Edelmann F, Mende M, Kockskamper A, Dungen HD, Scherer M, Kochen MM, Binder L, Herrmann-Lingen C, Gelbrich G, et al. Association of glucose metabolism with diastolic function along the diabetic continuum. Diabetologia 53:1331-1340. 2877336, 20386878, 10.1007/s00125-010-1718-8.
12. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. Diabetes 2004, 53:1782-1789. 10.2337/diabetes.53.7.1782, 15220202.
13. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002, 25:1135-1141. 10.2337/diacare.25.7.1135, 12087010.
14. Ingelsson E, Arnlov J, Sundstrom J, Zethelius B, Vessby B, Lind L. Novel metabolic risk factors for heart failure. J Am Coll Cardiol 2005, 46:2054-2060. 10.1016/j.jacc.2005.07.059, 16325042.
15. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003, 46:182-189.
16. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, Davila-Roman VG. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. J Am Coll Cardiol 2004, 43:1399-1404. 10.1016/j.jacc.2003.10.062, 15093874.
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
18. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009, 10:165-193. 10.1093/ejechocard/jep007, 19270053.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
20. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410. 10.1210/jc.85.7.2402, 10902785.
21. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702.
22. Paulus WJ, van Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol 55:526-537. 10.1016/j.jacc.2009.06.067, 20152557.
23. Dinh W, Futh R, Nickl W, Krahn T, Ellinghaus P, Scheffold T, Bansemir L, Bufe A, Barroso MC, Lankisch M. Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. Cardiovasc Diabetol 2009, 8:58. 2778641, 19909503, 10.1186/1475-2840-8-58.
24. Futh R, Dinh W, Nickl W, Bansemir L, Barroso MC, Bufe A, Sause A, Scheffold T, Krahn T, Ellinghaus P, Lankisch M. Soluble P-selectin and matrix metalloproteinase 2 levels are elevated in patients with diastolic dysfunction independent of glucose metabolism disorder or coronary artery disease. Exp Clin Cardiol 2009, 14:e76-79. 2807781, 20098572.
25. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001, 161:996-1002. 10.1001/archinte.161.7.996, 11295963.
26. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29-34. 10.1016/0002-9149(74)90089-7, 4835750.
27. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L. Insulin resistance and risk of congestive heart failure. Jama 2005, 294:334-341. 10.1001/jama.294.3.334, 16030278.
28. Bella JN, Palmieri V, Roman MJ, Liu JE, Welty TK, Lee ET, Fabsitz RR, Howard BV, Devereux RB. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle-aged and elderly adults: the Strong Heart Study. Circulation 2002, 105:1928-1933. 10.1161/01.CIR.0000015076.37047.D9, 11997279.
29. Wang M, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, Lam PK, Sanderson JE. Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. J Am Coll Cardiol 2003, 41:820-826. 10.1016/S0735-1097(02)02921-2, 12628728.
30. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 55:300-305. 10.1016/j.jacc.2009.12.003, 20117433.
31. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007, 115:3213-3223. 10.1161/CIRCULATIONAHA.106.679597, 17592090.
32. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure?. Circ Res 2004, 94:1533-1542. 10.1161/01.RES.0000129254.25507.d6, 15217918.
33. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113:1966-1973. 10.1161/CIRCULATIONAHA.105.587519, 16618817.
34. Stanley WC, Lopaschuk GD, McCormack JG. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Res 1997, 34:25-33. 10.1016/S0008-6363(97)00047-3, 9217869.
35. Bronzwaer JG, Paulus WJ. Nitric oxide: the missing lusitrope in failing myocardium. Eur Heart J 2008, 29:2453-2455. 10.1093/eurheartj/ehn393, 18772263.
36. Liedtke AJ, DeMaison L, Eggleston AM, Cohen LM, Nellis SH. Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium. Circ Res 1988, 62:535-542.
37. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991, 87:2246-2252. 296986, 2040704, 10.1172/JCI115260.
38. Gaboury CL, Simonson DC, Seely EW, Hollenberg NK, Williams GH. Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension. J Clin Invest 1994, 94:2295-2300. 330057, 7989585, 10.1172/JCI117593.
39. Sartori M, Ceolotto G, Papparella I, Baritono E, Ciccariello L, Calo L, Leoni M, Semplicini A. Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients. Am J Hypertens 2004, 17:604-610. 10.1016/j.amjhyper.2004.02.017, 15233979.
40. Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Br J Pharmacol 2001, 133:687-694. 1572838, 11429393, 10.1038/sj.bjp.0704131.
41. Park JS, Nam JS, Cho MH, Yoo JS, Ahn CW, Jee SH, Lee HS, Cha BS, Kim KR, Lee HC. Insulin resistance independently influences arterial stiffness in normoglycemic normotensive postmenopausal women. Menopause 17:779-784.
42. MacIsaac RJ, Thomas MC, Panagiotopoulos S, Smith TJ, Hao H, Matthews DG, Jerums G, Burrell LM, Srivastava PM. Association between intrarenal arterial resistance and diastolic dysfunction in type 2 diabetes. Cardiovasc Diabetol 2008, 7:15. 2413205, 18500986, 10.1186/1475-2840-7-15.
43. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. 10.1056/NEJMicm066227, 18539916.
44. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. 10.1056/NEJMoa0802743, 18539917.
45. Carson P, Johnson G, Fletcher R, Cohn J. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT). J Am Coll Cardiol 1996, 27:642-649. 10.1016/0735-1097(95)00503-X, 8606276.
46. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345. 10.1093/eurheartj/ehl250, 16963472.
47. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467. 10.1056/NEJMoa0805450, 19001508.
48. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781. 10.1016/S0140-6736(03)14285-7, 13678871.
49. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653. 2637991, 16371630, 10.1056/NEJMoa052187.
50. Piccini JP, Klein L, Gheorghiade M, Bonow RO. New insights into diastolic heart failure: role of diabetes mellitus. Am J Med 2004, 116(Suppl 5A):64S-75S. 10.1016/j.amjmed.2003.10.021, 15019864.
51. von Bibra H, Diamant M, Scheffer PG, Siegmund T, Schumm-Draeger PM. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diab Vasc Dis Res 2008, 5:310-318. 10.3132/dvdr.2008.045, 18958842.
52. Edelmann F, Pieske B. Diastolic Heart Failure. Diagnosis, Therapy and Impact of Exercise Training. Deutsche Zeitschrift für Sportmedizin 50:192-199.
53. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237:E214-223.
54. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, Shoji T, Okuno Y, Morii H. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999, 22:818-822. 10.2337/diacare.22.5.818, 10332688.